All In Biotech

Drug Trial Radar · NCT00309621

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis

Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Apr 2006

Primary completion

Apr 2007

Study completion May 2007

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Apr 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.

Conditions

  • Hand Dermatoses

Interventions

  • alitretinoinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety:
  2. Adverse Events
  3. Safety Laboratory
  4. Radiological investigations (bone density, x-ray)

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Québec, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Winnipeg, Manitoba, Canada

  • Site not named

    Hawkesbury, Ontario, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Markham, Ontario, Canada

  • Site not named

    Oakville, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Sheerbroke, Quebec, Canada

  • Site not named

    Berlin, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Cologne, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hamburg, Germany

  • Abt. Klinische Sozialmedizin

    Heidelberg, Germany

  • Site not named

    Ibbenbueren, Germany

  • Site not named

    Lübeck, Germany

  • Site not named

    Mönchengladbach, Germany

  • Site not named

    München, Germany

  • Site not named

    Münster, Germany

  • Site not named

    Osnabrück, Germany

  • Site not named

    Potsdam, Germany

  • Site not named

    Viersen, Germany

  • Site not named

    Wuppertal, Germany

  • Site not named

    Gdansk, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Opole, Poland

  • Site not named

    Szcecin, Poland

  • Site not named

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.